Fig. 1From: Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLCFlow diagram of the study. ALK+ NSCLC, anaplastic lymphoma kinase-positive non-small cell lung cancer; US, United States; FDA, Food and Drug AdministrationBack to article page